Haleon (HLN)
Haleon (HLN) Stock Price, Analysis & Data
| Bid | 9.87 |
| Market Cap | 43.48B |
| Revenue (ttm) | 11.15B |
| Net Income (ttm) | 1.62B |
| Beta | 0.24 |
| EPS (ttm) | 0.49 |
| PE Ratio (ttm) | 20.17 |
| Forward PE | 15.86 |
| P/B (ttm) | 1.98 |
| P/S (ttm) | 3.90 |
| Earnings Date | Feb 24, 2027 |
| Ask | 9.92 |
| Volume | 11,337,180 |
| Avg. Volume (20D) | 9,524,391 |
| Open | 9.81 |
| Previous Close | 9.72 |
| Day's Range | 9.79 - 9.96 |
| 52-Week Range | 8.65 - 11.28 |
| Analyst | Buy |
| Price Target | 12.4 (25.63%) |
| Dividends | $0.2 (2%) |
| Ex-Dividend Date | Aug 14, 2026 |
About HLN
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum...
Financial Performance
In 2025, Haleon's revenue was 11.03B, a decrease of -1.81% compared to the previous year's 11.23B. Earnings were 1.67B, an increase of 15.6%.
Financial StatementsAnalyst Forecast
According to 5 analyst ratings, the average rating for HLN stock is "Buy". The 12-month stock price forecast is 12.4, which is upside of 25.63% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
